GE Healthcare announces FDA approval of SenoClaire

The Food and Drug Administration has approved SenoClaire, GE Healthcare's new breast tomosynthesis solution designed with three-dimensional imaging technology.

SenoClaire technology, which was developed through collaboration with Massachusetts General Hospital in Boston, uses a low-dose short X-ray sweep around the positioned breast with nine exposures acquired with a "step-and-shoot" method, removing the potential motion from the tube helping to reduce blue and increase image sharpness.

SenoClaire can help with the early detection of breast cancer. "When cancer is identified and treated earlier, we know women have a better rate of survival," said Daniel Kopans, senior radiologists, breast imaging department of radiology, Massachusetts General Hospital. 

More articles on health technology:

Providence launches $150M IT-focused venture capital fund
Analytics in the era of value-based care
3 things the most innovative health systems do